While initially developed to lower blood sugar in patients with diabetes mellitus (DM), SGLT2 inhibitors reduce the risk of kidney failure and other major kidney outcomes by 30%–40% over 2–3 years in clinical trials including individuals with CKD, with or without DM.1, –3 Given these consequential results, SGLT2-inhibitors are now a cornerstone of CKD therapy. This evidence concerns the gene SLC5A2 and kidney failure.